Want to see AU:MAP full AI Analyst Report?
MAP Stock Chart & Stats
AU$0.06
<AU$0.01(2.22%)
At close: 4:00 PM EDT
AU$0.06
<AU$0.01(2.22%)
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.11
Previous CloseN/A
Volume296.78K
Average Volume (3M)417.20K
Market Cap
AU$32.27M
Enterprise ValueAU$18.34M
Total Cash (Recent Filing)AU$7.95M
Total Debt (Recent Filing)AU$4.11M
Price to Earnings (P/E)―
Beta0.90
Next Earnings
Mar 03, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding717,117,250
10 Day Avg. Volume326,226
30 Day Avg. Volume417,202
Financial Highlights & Ratios
PEG Ratio-0.29
Price to Book (P/B)0.89
Price to Sales (P/S)1.47
P/FCF Ratio-1.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$0.08Price Target Upside41.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.01
Revenue Forecast (FY)AU$19.83M
Bulls Say, Bears Say
Bulls Say
Low LeverageManageable leverage reduces near-term solvency pressure and preserves some financial flexibility while the company develops its microbiome platform. A relatively modest debt burden can also limit interest-related strain and provide more room for future funding or strategic investment.
Specialised Microbiome PlatformA focused microbiome capability spanning measurement, laboratory processing, bioinformatics and interpretation gives the company a defined platform across research, clinical decision-making and therapeutic development. This broad application base supports multiple potential commercial pathways.
Revenue Base Above Early YearsRevenue remaining materially above the company’s early-year level indicates that the business has achieved some underlying commercial scale over time. That established revenue base can support further customer development and operating leverage if profitability improves.
Bears Say
Persistent Cash ConsumptionPersistent negative operating and free cash flow means the business is not yet self-funding its operations and investment needs. Continued deterioration in 2026 increases dependence on external capital, potentially limiting strategic flexibility and exposing shareholders to future funding pressure.
Deep And Worsening LossesNegative gross profit and very large operating losses show that the current revenue base does not yet support the cost structure. Until the company improves unit economics and margins, growth may continue to consume capital rather than translate into durable earnings or cash generation.
Eroding Equity BaseMaterial equity erosion reduces the capital cushion available to absorb continued operating losses and fund development activities. Although leverage is low, sustained deterioration in the equity base can increase reliance on external funding and weaken long-term shareholder value retention.
Microba Life Sciences Limited News
MAP FAQ
What was Microba Life Sciences Limited’s price range in the past 12 months?
Microba Life Sciences Limited lowest share price was AU$0.04 and its highest was AU$0.10 in the past 12 months.
What is Microba Life Sciences Limited’s market cap?
Microba Life Sciences Limited’s market cap is AU$32.27M.
When is Microba Life Sciences Limited’s upcoming earnings report date?
Microba Life Sciences Limited’s upcoming earnings report date is Mar 03, 2027 which is in 140 days.
How were Microba Life Sciences Limited’s earnings last quarter?
Microba Life Sciences Limited released its earnings results on Sep 01, 2026. The company reported -AU$0.016 earnings per share for the quarter, missing the consensus estimate of -AU$0.006 by -AU$0.01.
Is Microba Life Sciences Limited overvalued?
According to Wall Street analysts Microba Life Sciences Limited’s price is currently Undervalued.
Does Microba Life Sciences Limited pay dividends?
Microba Life Sciences Limited does not currently pay dividends.
What is Microba Life Sciences Limited’s EPS estimate?
Microba Life Sciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Microba Life Sciences Limited have?
Microba Life Sciences Limited has 717,117,250 shares outstanding.
What happened to Microba Life Sciences Limited’s price movement after its last earnings report?
Microba Life Sciences Limited reported an EPS of -AU$0.016 in its last earnings report, missing expectations of -AU$0.006. Following the earnings report the stock price went up 3.704%.
Which hedge fund is a major shareholder of Microba Life Sciences Limited?
Currently, no hedge funds are holding shares in AU:MAP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Microba Life Sciences Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
AU$0.08 (41.67% Upside)
AU$0.08 (41.67% Upside)
Blogger Sentiment
Bullish
AU:MAP Sentiment 100%
Sector Average 67%
Sector Average 67%
Insider Transactions
Bought Shares
Worth AU$72.5K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.78%
12-Months-Change
Fundamentals
Return on Equity
-75.96%
Trailing 12-Months
Asset Growth
-16.08%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Microba Life Sciences Limited
Microba Life Sciences Limited, established in Brisbane, Australia, in 2017, specializes in providing sophisticated microbiome testing and analytical services. These offerings reach clinicians, individual consumers, and research customers across key international markets, including Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, and the United States. The company delivers pathology, therapeutic, and diagnostic solutions deeply rooted in human gut microbiome science. Central to its operations is a comprehensive Databank, invaluable for unearthing therapeutic leads, fostering consumer health advancements, and identifying crucial diagnostic biomarkers. Moreover, Microba leverages a data-driven therapeutics platform to engineer innovative monoclonal microbial cell therapies aimed at treating inflammatory bowel disease, enhancing cancer immunotherapy, and managing autoimmune disorders.
MAP Stock 12 Month Forecast
Average Price Target
AU$0.08
▲(41.67% Upside)
Technical Analysis
―
BCAL Diagnostics Limited
―
Rhythm Biosciences Ltd.
―
Lumos Diagnostics Holdings Ltd.
―
Genetic Signatures Ltd.
―